Literature DB >> 18094417

BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.

Madeleine M A Tilanus-Linthorst1, Inge-Marie Obdeijn, Wim C J Hop, Petrina A Causer, Martin O Leach, Ellen Warner, Linda Pointon, Kimberley Hill, Jan G M Klijn, Ruth M L Warren, Fiona J Gilbert.   

Abstract

PURPOSE: Magnetic resonance imaging (MRI) screening enables early detection of breast cancers in women with an inherited predisposition. Interval cancers occurred in women with a BRCA1 mutation, possibly due to fast tumor growth. We investigated the effect of a BRCA1 or BRCA2 mutation and age on the growth rate of breast cancers, as this may influence the optimal screening frequency. EXPERIMENTAL
DESIGN: We reviewed the invasive cancers from the United Kingdom, Dutch, and Canadian MRI screening trials for women at hereditary risk, measuring tumor size at diagnosis and on preceding MRI and/or mammography. We could assess tumor volume doubling time (DT) in 100 cancers.
RESULTS: Tumor DT was estimated for 43 women with a BRCA1 mutation, 16 women with a BRCA2 mutation, and 41 women at high risk without an identified mutation. Growth rate slowed continuously with increasing age (P = 0.004). Growth was twice as fast in BRCA1 (P = 0.003) or BRCA2 (P = 0.03) patients as in high-risk patients of the same age. The mean DT for women with BRCA1/2 mutations diagnosed at ages < or =40, 41 to 50, and >50 years was 28, 68, and 81 days, respectively, and 83, 121, and 173 days, respectively, in the high-risk group. Pathologic tumor size decreased with increasing age (P = 0.001). Median size was 15 mm for patients ages < or =40 years compared with 9 mm in older patients (P = 0.003); tumors were largest in young women with BRCA1 mutations.
CONCLUSION: Tumors grow quickly in women with BRCA1 mutations and in young women. Age and risk group should be taken into account in screening protocols.

Entities:  

Mesh:

Year:  2007        PMID: 18094417     DOI: 10.1158/1078-0432.CCR-07-0689

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Breast Cancer Screening in High-Risk Women: Is MRI Alone Enough?

Authors:  Carolina Rossi Saccarelli; Almir G V Bitencourt; Elizabeth A Morris
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

2.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Bronislava M Sigal; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

Review 4.  Intensified surveillance for early detection of breast cancer in high-risk patients.

Authors:  Ulrich Bick
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

5.  Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  I Trop; L Lalonde; M H Mayrand; J David; N Larouche; D Provencher
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

6.  Online tool to guide decisions for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Diego F Munoz; Peter Rust; Elizabeth A Schackmann; Michael Smith; Lauren Clarke; Meredith A Mills; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

7.  Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.

Authors:  Victorien Mt van Verschuer; Bernadette Am Heemskerk-Gerritsen; Carolien Hm van Deurzen; Inge-Marie Obdeijn; Madeleine Ma Tilanus-Linthorst; Cornelis Verhoef; Marjanka K Schmidt; Linetta B Koppert; Maartje J Hooning; Caroline Seynaeve
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

8.  Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound.

Authors:  Eun Bi Ryu; Jung Min Chang; Mirinae Seo; Sun Ah Kim; Ji He Lim; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2014-06-04       Impact factor: 5.315

9.  Is there a role for routine screening MRI in women with LCIS?

Authors:  Tari A King; Shirin Muhsen; Sujata Patil; Starr Koslow; Sabine Oskar; Anna Park; Mary Morrogh; Rita A Sakr; Monica Morrow
Journal:  Breast Cancer Res Treat       Date:  2013-10-19       Impact factor: 4.872

10.  Stemming the tide of cancer for BRCA1/2 mutation carriers.

Authors:  Henry T Lynch; Joseph N Marcus; Wendy S Rubinstein
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.